We operate with integrity, trust and respect within our company.



We engage directly with your team to find suitable solutions in accordance with your criteria. We operate with integrity, trust and respect within our company and in the lasting win-win partnership we have formed with our customers.

About Us

Health and 

Safety Training

Handling Complaints 

and Recalls

Quality Policies

and Manuals

GMP Training

Technical Writing

Clean Labels



Finish Product

Specifications and

Formulation Development

eCTD Submissions

NPN Licensing

Register with us for more information

Contact Us


Under the Canada Labor Code Part II, it is the employer’s obligation to adequately train employees, supervisors and managers in health and safety responsibilities.
AlphaGreen Resources Inc. mission is to deliver professional, knowledgeable training that insure companies will meet their workplace Health and Safety goals.
We help our clients reduce the risk of accidents and injuries, while giving them the tools to develop their own safety programs from the ground up.
Our certified trainers offer a wide range of On-Site, Workplace Safety Training from, WHMIS/GHS, Worker Awareness, Joint Work Site Health and Safety Committee Training, Safety & Human Resources Training and much more.
Contact us at: info@alphagreenresources.com



A site licence is required for the physical site in Canada where any business wish to manufacture, package, label, and/or import a Natural Health Product (NHP) for sale.
Sites must have procedures in place for distribution records and product recalls and for the handling, storage and delivery of their products. They must also demonstrate that they meet good manufacturing practice requirements.
To ensure a smooth NHP Site Licensing process, AlphaGreen Resources Inc. team will work with you to review your site’s Standard Operating Procedures (SOPs) and associated documentation against Good Manufacturing Practices (GMPs).
We will prepare and submit all necessary documentation and liaise with the NNHPD on your behalf.
Contact us at: info@alphagreenresources.com


All Natural Health Products (NHPs) that are targeting the Canadian market are subject to the Natural Health Products Regulations, which came into effect on January 1, 2004
All Natural Health Products must have a product license and a Natural Product Number (NPN) before they can be sold anywhere in Canada.
AlphaGreen Resources Inc. has successfully registered over 7000 Natural Health Products (NHPs) since 2009, serving over 1000 clients.
The category of NHPs includes vitamins, minerals, herbal products, traditional medicines such as ayurvedic and traditional Chinese medicines, probiotics and other products like amino acids and essential fatty acids.
Contact us at: info@alphagreenresources.com


For more than 50 years, dietary guidelines in the United States and Canada have focused on reducing intakes of saturated and total fat. However, rates of obesity and diabetes rose markedly throughout this period, with potentially catastrophic implications for public health and the economy.
Recently, ketogenic diets have received substantial attention from the general public and nutrition research community. These very-low-carbohydrate diets, with fat comprising more than 70% of calories, have been dismissed as fads.
Ketogenic diets appear to be more effective than low-fat diets for treatment of obesity and diabetes. In addition to the reductions in blood glucose and insulin achievable through carbohydrate restriction, chronic ketosis might confer unique metabolic benefits of relevance to cancer, neurodegenerative conditions, and other diseases associated with insulin resistance. Based on available evidence, a well-formulated ketogenic diet does not appear to have major safety concerns for the general public and can be considered a first-line approach for obesity and diabetes. High-quality clinical trials of ketogenic diets will be needed to assess important questions about their long-term effects and full potential in clinical medicine.
David S Ludwig (The Journal of Nutrition, Volume 150, Issue 6, June 2020)



Chlorella is one green superfood that is a virtual paragon of nutrition, and is believed to contain the most chlorophyll of any plant. Chlorella also contains numerous vitamins, carotenoids, minerals, amino acids, fatty acids, beta-glucans, protein, fiber and chlorella growth factor (CGF). The polysaccharides in chlorella stimulate the production of interferon, file fuel your body’s immune system needs to work at its full capacity.
In terms of chronic disease, chlorella was first shown to decrease the side effects of chemotherapy and arrest the growth of some cancer cell lines in the 1960s, according to the American Cancer Society. And a human study published in the Fall 2002 Journal of Medicinal Food showed that chlorella supplementation improved blood pressure. A combination of liquid and tablet chlorella supplements reduced the tenderness experienced by fibromyalgia patients by 22 percent, according to researchers working at the Virginia Commonwealth University School of Medicine in Richmond.
As more and more people begin to pay closer attention to their dietary habits, chlorella is set to burst into the mainstream. After all, Chlorella as one of the world’s healthiest foods.
Kim Shoenhals (Better Nutrition,Vol. 66, Issue 10)


Adequate vegetable consumption is one of the cornerstones of a healthy diet. The recommendation to increase vegetable intake is part of most dietary guidelines. Despite widespread and long-running public health messages to increase vegetable intake, less than 1 in 10 adult manage to meet target advice. Identifying vegetables with the strongest health benefits and incorporating these into dietary recommendations may enhance public health initiatives around vegetable intake.
The amount of vegetable intake recommended in dietary guidelines vary globally, but is usually around 5–6 servings/day (375–450 g/day).
Increasing vegetable intake, with a focus on consuming leafy green and cruciferous vegetables provide the greatest cardiovascular health benefits. Incorporating such dietary changes along with other recommended lifestyle changes will optimize health benefits. Lifestyle changes include consuming a diet full of vegetable, fruits, and whole grains; including low-fat dairy products, poultry, fish, legumes, non-tropical vegetable oils, and nuts; and limiting intake of saturated and trans fats, sweets, sugar-sweetened beverages, and red meats. Other lifestyle changes include increasing physical activity, avoiding cigarette smoking, and intake of alcohol, and maintaining a healthy body weight by consuming appropriate energy requirements.
(Cardiovascular Health Benefits of Specific Vegetable Types: A Narrative Review, MDPI Nutients, 10(5) , 595)



Tobacco is the leading preventable cause of premature death and disease in Canada. Although progress has been made over the years to reduce tobacco use among Canadians, it continues to be a significant public health problem. We’re also seeing troubling trends of vaping among youth, which poses risks to the health of young Canadians, and can also lead to nicotine addiction. To mark World No Tobacco Day, the Honourable Patty Hajdu, Minister of Health, announced nearly $4.8 million in funding for organizations across Canada to develop programs and services that will help stop tobacco use among Canadians, and reduce youth vaping. The Government of Canada knows the significant health harms associated with smoking and youth vaping, which is why we continue to implement Canada’s Tobacco Strategy. We’ve invested close to $330-million in this strategy, which aims to reduce tobacco use to less than 5% by 2035, to help Canadians quit smoking and to continue to protect young people and non-smokers from nicotine addiction. We know that quitting smoking and using tobacco is not easy, and those who want to quit don’t have to do it alone. We will continue working in partnership with organizations across the country to reduce vaping among youth and to keep all Canadians safe and healthy.
News Release (31 May 2020, Ottawa, Ontario, Health Canada)



RNA viruses, including poliovirus, respiratory syncytial virus, picornaviruses, influenza virus, and coronavirus can all be stopped at the cellular level by increasing the intracellular concentration of zinc. Medical researchers from the Molecular Virology Laboratory, Department of Medical Microbiology, Center of Infectious Diseases, Leiden University Medical Center, in the Netherlands explain that the replication of all these viruses can be stopped when zinc concentrations force a correction of proteolytic processing of viral polyproteins. Using electromobility shift assays (EMSA) in the presence and absence of Zn2+, the researchers measured the binding affinity of the viral RNA and measured a 3-4 fold reduction in RNA-dependent RNA polymerase binding in the presence of zinc. By using zinc ionophores like pyrithione, the researchers proved that increased intracellular zinc impairs the replication of RNA viruses, severely inhibiting the replication of equine arteritis virus (EAV) and SARS-coronavirus (SARS-CoV) in cells. The two viruses share a core enzyme needed for multi-protein replication that is easy to block using zinc. The researchers didn’t even need to rely on pyrithione to transport zinc across the plasma membrane because zinc could effectively inhibit RNA synthesizing activity in a direct manner. Because of this, the in vitro activity of both viruses polymerases could be blocked with ease. Moreover, zinc was found to specifically block the initiation step of RNA synthesis, inhibiting the elongation and template binding of SARS-CoV RNA-dependent RNA polymerase. The researchers also showed that the absence of zinc, through chelation of the mineral from cells, reverses its therapeutic effect, allowing viral replication to continue. Dr Eddy Bettermann MD ( June 10,2020, DREDDYMD, Diseased &Disorder, Immune System)



The COVID-19 pandemic has led to a global search for therapies to treat, diagnose, mitigate or prevent the infection. Before new therapies can be made available to Canadians, they must be shown to be safe and effective, and clinical trials are a critical part of that process. To date, Health Canada has approved 37 clinical trials for potential COVID-19 therapies and vaccines. To accelerate these efforts, the Honourable Patty Hajdu, Minister of Health, has authorized the following change for a more flexible process for clinical trials related to COVID-19, without compromising the safety of participants or the reliability of trials’ findings: Allow a wider range of health professionals, such as nurse practitioners, to be involved in running clinical trials. Under current regulations, only physicians and dentists can conduct clinical trials for drugs; Allow a wider range of investigators, such as physicians, to be involved in running clinical trials for medical devices. Under current regulations, only manufacturers can conduct clinical trials for medical devices; Reduce the burden associated with labelling and record-keeping requirements for clinical trials involving drugs that are already marketed for other indications and are being studied to treat COVID-19; Enable multiple-stream clinical trials to continue even when one stream has been stopped; and Enable more clinical trials by allowing trials where direct interaction with the participant is not feasible, for example when participants who live in remote. News release (May 27, 2020 – Ottawa , Ontario – Health Canada)